Treatment with neoadjuvant BRAF Inhibition Yields Responses in Patients (pts) with High Risk Borderline Resectable Stage III Melanoma.
Year: 2015
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Rodabe Navroze Amaria, Jennifer Ann Wargo, Zachary A Cooper, Michael T. Tetzlaff, Alexandre Reuben, Michael A. Davies, Jeffrey E. Gershenwald, Hong Jiang, Jacob Austin-Breneman, Jeffrey Edwin Lee, Patrick Hwu, Wen-Jen Hwu, Janice N. Cormier, Richard Eldon Royal, Anthony Lucci, Sapna Pradyuman Patel, Adi Diab, Isabella Claudia Glitza, Elizabeth M Burton, Merrick I. Ross
Institution: The University of Texas MD Anderson Cancer Center
Language: English
Topic: Melanoma and MAPK Pathways
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W2613260928